Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics

Anti-CD20 monoclonal antibodies (mAbs) rituximab and ofatumumab are potent activators of the classical complement pathway, and have been approved for the treatment of B-cell malignancies. However, complement exhaustion and overexpression of complement inhibitors by cancer cells diminish their therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Felberg, Anna, Urban, Aleksandra, Borowska, Anna, Stasiłojć, Grzegorz, Taszner, Michał, Hellmann, Andrzej, Blom, Anna Maria, Okrój, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447516/
https://www.ncbi.nlm.nih.gov/pubmed/30725204
http://dx.doi.org/10.1007/s00262-019-02304-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447516/
https://www.ncbi.nlm.nih.gov/pubmed/30725204
http://dx.doi.org/10.1007/s00262-019-02304-0

Ejemplares similares